{
    "symbol": "INM",
    "quarter": 4,
    "year": 2022,
    "date": "2022-09-23 15:28:08",
    "content": " Over the next several months, shareholders should expect to see the following catalysts: completion of the Phase 2 clinical trial with the data readout expected in the first quarter of calendar 2023; complete the IND-enabling toxicology program and the INM-088 program for glaucoma by end of calendar year 2023; candidate selection for the neurodegenerative disease category in the second quarter of 2023; further execution on our preclinical R&D and patent strategies for proprietary cannabinoid analogs; and we will remain opportunistic to business development in the pharmaceutical drug R&D arena to build shareholder wealth."
}